Nordea Investment Management Ab Blueprint Medicines Corp Transaction History

Nordea Investment Management Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$45.23 - $70.15 $136,911 - $212,344	-3,027 Reduced 8.69%	31,810 $1.59 Million
Q4 2021 Jan 20, 2022	SELL	$94.25 - $115.99 $45,522 - $56,023	-483 Reduced 1.37%	34,837 $3.87 Million
Q3 2021 Nov 01, 2021	SELL	$80.98 - $109.47 $2.86 Million - $3.87 Million	-35,320 Reduced 50.0%	35,320 $3.69 Million
Q3 2021 Nov 01, 2021	BUY	$80.98 - $109.47 $5.72 Million - $7.73 Million	70,640 New	70,640 $7.26 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

Stay updated on Nordea Investment Management Ab with notifications on news.